Home > Insider Trading > Filing (0000950103-20-015725)

Filing Details

Accession Number:: 0000950103-20-015725
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2020-08-12 21:06:57
Reporting Period:: 2020-08-10

Accepted Time:: 2020-08-12 21:06:57
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1522860	Acutus Medical Inc.	AFIB	Surgical & Medical Instruments & Apparatus (3841)	451306615

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1572451	P David Bonita	C/O Acutus Medical, Inc. 2210 Faraday Ave., Suite 100 Carlsbad CA 92008		Yes	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2020-08-10	373,500	$18.00	373,500	No	4	P	Indirect	See footnotes
Common Stock	Acquisiton	2020-08-10	41,500	$18.00	41,500	No	4	P	Indirect	See footnotes
Common Stock	Acquisiton	2020-08-10	3,784,240	$0.00	4,157,740	No	4	C	Indirect	See footnotes
Common Stock	Acquisiton	2020-08-10	1,278,718	$0.00	1,320,218	No	4	C	Indirect	See footnotes

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	See footnotes
No	4	P	Indirect	See footnotes
No	4	C	Indirect	See footnotes
No	4	C	Indirect	See footnotes

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series B Convertible Preferred Stock	Disposition	2020-08-10	872,302	$0.00	872,302	$0.00
Common Stock	Series B Convertible Preferred Stock	Disposition	2020-08-10	673,123	$0.00	673,123	$0.00
Common Stock	Series C Convertible Preferred Stock	Disposition	2020-08-10	647,582	$0.00	647,582	$0.00
Common Stock	Series C Convertible Preferred Stock	Disposition	2020-08-10	899,985	$0.00	899,985	$0.00
Common Stock	Series D Convertible Preferred Stock	Disposition	2020-08-10	389,116	$0.00	389,116	$0.00
Common Stock	Series D Convertible Preferred Stock	Disposition	2020-08-10	1,202,117	$0.00	1,202,117	$0.00
Common Stock	Series D Convertible Preferred Stock	Disposition	2020-08-10	378,733	$0.00	378,733	$0.00

Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	2,222	Direct

Footnotes

These securities are held of record by OrbiMed Private Investments IV, LP ("OPI IV"). OrbiMed Capital GP IV LLC ("GP IV") is the general partner of OPI IV. OrbiMed Advisors LLC ("OrbiMed Advisors"), a registered investment adviser under the Investment Advisers Act of 1940, as amended, is the managing member of GP IV. The Reporting Person is a member of OrbiMed Advisors. By virtue of such relationships, GP IV and OrbiMed Advisors may be deemed to have voting and investment power over the securities held by OPI IV and as a result may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the shares held by OPI IV.
These securities are held of record by OrbiMed Royalty Opportunities II, LP ("ORO II"). OrbiMed ROF II LLC ("ROF II") is the general partner of ORO II. OrbiMed Advisors is the managing member of ROF II. The Reporting Person is a member of OrbiMed Advisors. By virtue of such relationships, ROF II and OrbiMed Advisors may be deemed to have voting and investment power over the securities held by ORO II and as a result may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the shares held by ORO II.
Each of GP IV, ROF II, OrbiMed Advisors and the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its pecuniary interest therein, if any. This report on Form 4 shall not be deemed an admission that the Reporting Person is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose. The Reporting Person was designated as a representative by OrbiMed Advisors to serve on the Issuer's board of directors.
Each of the Series B Convertible Preferred Stock, Series C Convertible Preferred Stock and Series D Convertible Preferred Stock is convertible into the Issuer's Common Stock on a one-for-one basis for no additional consideration and has no expiration date.